Association of Comorbidities With COVID19

COVID19 Clinical Trial

Official title: Impact of Comorbidities on COVID19 Outcome

Status Recruiting

Clinical Trial Summary

Association of Comorbidities with unfavorable COVID19 outcomes as admission to intensive care, invasive ventilation or death.

Clinical Trial Description

COVID19 is a new emerging, rapidly disseminating disease that consuming most of resources of efficient healthcare systems, and several hospitals, worldwide, are currently experiencing a shortage of ICU beds for critically ill patients with COVID-19 pneumonia.

A risk stratification based on clinical, radiological and laboratory parameters seems necessary in order to better identify those patients who may need hospital and/or ICU admission.

One of the most alarming clinical parameters in general is the presence comorbidities. The underlying diseases including hypertension, diabetes mellitus, respiratory system disease and cardiovascular disease, may be risk factors for severe COVID-19 patients with adverse outcomes compared with non-severe patients. Obesity is also a risk factor for COVID-19 severity with increased need to mechanical ventilation.

Chronic diseases share several features with infectious disorders, such as the proinflammatory state, and the attenuation of the innate immune response which may be linked etiologically to its pathogenesis.

Aim of the study:to assess the impact of comorbidities in patients with diagnosis of Covid-19 on outcome, in order to find the predictors of prolonged hospital stay, need for ICU admission or poor outcome ;

Related Conditions & MeSH terms

• COVID19

• NCT number: NCT04459390
• Study type: Observational
• Source: Assiut University
• Contact: Hebatallah Hassan
• Phone: 01022182086
• Email: heba.ismailhassan@gmail.com
• Status: Recruiting
• Start date: July 20, 2020
• Completion date: November 20, 2020